Abstract Library

#4583 Improved assessment of gene rearrangements by targeting non-coding DNA regions in patients diagnosed with pancreatic neuroendocrine neoplasms

Introduction: Whole-genome sequencing projects documented the heterogeneity of pancreatic neuroendocrine neoplasms (PanNEN), while showing that few core pathways are consistently affected in their tumorigenesis. Comprehensive genomic profiling (CGP) of real-world cases is expected to recapitulate such heterogeneity for patient stratification and to inform precision therapy. While coding DNA is the focus of current CGP panels, the potential of targeting non-coding DNA (ncDNA) to improve structural variants detection has not been widely explored in this context.

Conference:

Presenting Author: Agnoletto C

Authors: Agnoletto C, Trevisani E, Borghesani M, Landoni L, Luchini C,

Keywords: neuroendocrine, non-coding DNAs, structural variants, clinical relevance, CGP panel,

#4557 miR-1290 and miR-320c regulate cell proliferation and predict patient prognosis in neuroendocrine carcinomas

Introduction: The biology of neuroendocrine carcinomas (NECs) remains largely unknown, limiting the use of biomarkers for patient stratification and therapy response prediction in clinical practice.

Conference:

Presenting Author: Liverani C

Authors: Liverani C, Sgolacchia F, Bongiovanni A, Calabrese C, Vanni S,

Keywords: biomarker, miRNAs, neuroendocrine carcinoma,

#4383 Clinical and biological heterogeneity of grade 2 gastroenteropancreatic neuroendocrine neoplasms (GEP NENs): Prognostic significance of the 10% Ki-67 index cutoff and implications for treatment strategies

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) are a diverse group of neoplasms with varying prognoses. Grade 2 (G2) tumours, with a Ki-67 index between 3%-20%, present management challenges due to their intermediate behaviour, with evidence suggesting distinct outcomes between Ki-67

Conference:

Presenting Author: Massironi S

Authors: Massironi S, Coltro L, Gallo C, Preatoni P, Dell' Anna G,

Keywords: Neuroendocrine neoplasm, Ki-67 Index, Grade 2 Neuroendocrine Tumour, Neoplasm Grading, Tumour Heterogeneity, Progression-Free Survival (PFS), Peptide Receptor Radionuclide Therapy,

#4340 Predominant volumetric phenotype in dual PET and overall survival in NENs

Introduction: Dual 18F-FDG/68Ga-DOTATATE PET can predict NEN prognosis and guide treatment choice. However, research to date (such as the NEPTET score) has focused on the dual PET phenotype of single-point lesions rather than of the total disease volume.

Conference:

Presenting Author: Chan D

Authors: Chan D, Bernard E, Mokhtar S, Chou A, Gill A,

Keywords: Prognostic biomarker, PET/CT, tumour volume, 18F-FDG, 68Ga-DOTATATE,

#4219 MAPK and mTOR pathway activation is associated with chemotherapy resistance and a poor prognosis in G3 advanced NENs

Introduction: Neuroendocrine neoplasms (NENs) comprise a broad spectrum of disease ranging from slowly progressive to highly aggressive carcinomas.

Conference:

Presenting Author: Catoya J

Authors: Catoya J, Anton-Pascual B, Farinea G, Modrego A, La Salvia A,

Keywords: NEN, mTOR/MAPK pathway, molecular profiling, platinum-based,